W.L. Gore and Associaties, Inc. the 2013 Arizona Bioscience Company of the Year
W.L. Gore & Associates was honored at the 2013 AZBio Awards as the Arizona Bioscience Company of the Year by the Arizona Bioindustry Association in recognition of the development of the extensive Gore Medical family of products including vascular grafts, endovascular and interventional devices, and surgical meshes by its world class team of innovators in Flagstaff and Phoenix. In this video you will learn about Gore and also gain insights on what we need to do together to continue our Arizona Bioscience Industry growth from Gore's Kurt Long.
Biotech Gore Tag Endoprosthesis
The Gore Medical Products Division has provided creative therapeutic solutions to complex medical problems for more than 35 years. During that time, more than 30 million innovative Gore Medical Devices have been implanted worldwide. The extensive Gore Medical family of products includes vascular grafts, endovascular and interventional devices, surgical meshes for hernia repair, soft tissue reconstruction, staple line reinforcement and sutures for use in vascular, cardiac and general surgery.
Flagship Biosciences - AZBio Company of the Year | 2012 Finalist
Flagship Biosciences provides quantitative tissue analysis services for pharmaceutical and medical device development. Flagship offers a broad range of tissue assessment options, achieved through a diverse set of approaches. Flagship Biosciences provides tissue analysis solutions to over sixty biotech, pharmaceutical, and medical device clients, with global programs in place for tissue-based companion diagnostics with three of the largest pharmaceutical companies in the world. Their sales grew 400% in 2011, and are on track to triple again in 2012. Flagship scientists published seven peer-reviewed articles in 2011, and filed 4 patent applications during the year. However, the largest development for Flagship was the acquisition of a histology and immunohistochemistry laboratory during the close 2011 which has added tissue procurement to complete their tissue-based analysis operations. Finally, the company’s image analysis technology won a best poster award at the Pathology Visions 2011 conference in San Diego, and a best presentation award at the Pathology Informatics 2011 meeting in Pittsburgh The company is currently working on a medical device spinout of their existing operations and expansion into Phoenix later this year. Committed to growing not only the company but also Arizona’s bioscience talent pool, the company currently utilizes many students from Northern Arizona University. Flagship Biosciences was honored in 2011 with the 2011 AZBio Fast Lane Award .
Nasseo moves into the Fast Lane
Nasseo, Inc. is a start-up medical device company developing an implant surface modification technology to provide patients and clinicians with the next generation of dental and orthopedic implants. Over the past 18 months the company has achieved very impressive milestones and is in the Fast Lane to delivering a new platform technology that benefits patients in several compelling markets. In 2013 NASSEO was accepted into the BioInspire Medical Device accelerator in Peoria, AZ. In addition to mentoring and support, NASSEO received a $300,000 investment of seed funding from the highly competitive program. NASSEO was also named the 2013 Innovation Challenge Winner by the Arizona Commerce Authority (ACA) in its spring Arizona Innovation Challenge securing $250,000 for the commercialization of its first product, the TiArray™ Dental Implant which received FDA approval in 2013.
2012 AZBio Fast Lane Award Winner - Ulthera
Beauty and Growth – Ulthera, Inc Ulthera’s mission is to work with physicians to provide therapeutic ultrasound to improve the appearance and health of patients worldwide. The company is not only defined by its proprietary technology, but also its people. Ulthera’s team consists of experts in their respective fields who are aligned by the strength of the company’s mission and its leadership. Ulthera was founded in 2004 to leverage seven years of prior scientific research in therapeutic ultrasound for aesthetic and medical applications. In 2009, the Ulthera® System received FDA approval in the United States and is the first and only energy-based device to receive FDA clearance for a non-invasive aesthetic lift indication. The first application for Ultherapy® – the procedure enabled by the System – is a non-invasive treatment of the face to achieve a brow lift. Ulthera’s robust scientific foundation and relentless pursuit of superior clinical outcomes have resulted in the rapid global uptake of the Ulthera platform. As Ulthera continues to develop and provide more applications for its platform, the company also remains committed to bringing value to physicians and their patients. In 2006, Matt Likens was hired as President and CEO of Ulthera by founder and owner Michael Slayton, Ph. D, with the expectation of obtaining FDA approval for Ulthera’s product and service (known as Ultherapy) within three months. Less than two years into his tenure at Ulthera, Matt found himself navigating this venture capital backed start-up though the worst economic downtown since the Great Depression. The Company also found itself facing an increasing skeptical and less commercially friendly US Food and Drug Administration (FDA) regime. With both of these risks significantly threatening the Company’s viability, Matt decided to change the Company’s regulatory pathway and focus by obtaining CE Mark from the European Union prior to obtaining FDA clearance. If this bet paid off, Ulthera’s regulatory runway would be significantly reduced and the Company would be able to generate sales in the European market. These revenues would also allow the Company to lessen the need to obtain additional venture capital financing thus reducing additional dilution to the Company’s current shareholders. While risky, the core of this decision was based on the multinational experience Likens attained at Baxter and his general entrepreneurial nature. The bet ultimately paid off. Today, Ulthera is a global, growth-stage medical device company pioneering aesthetic and medical applications using its therapeutic ultrasound platform technology. More than 1,000 Ulthera Systems have been sold globally while treatments performed using the System have surpassed 100,000.
Yulex moves into the AZBio Fast Lane
http://www.yulex.com/ Rubber and commerce go hand in hand and rubber products are everywhere. Yulex Corporation is the global leader in guayule-based biomaterials for a wide range of markets and diverse applications. Yulex’s Guayule BioRubber Emulsions and BioRubber Solids have medical, consumer, and industrial applications to grow an increasingly diverse market community with ultra-pure, high-performance products. From medical devices to fabric coatings, and from bedding to industrial packaging adhesives, Yulex also provides technical and product development guidance and support, and even custom material compounding and formulation. Yulex Corporation, a technology, marketing and biomaterial product development company that applies sustainable crop science, clean bioprocessing, and materials science for the production of natural, allergy-friendly BioRubber derived from the renewable, crop Guayule was honored with the 2013 AZBio Fast Lane Award from the Arizona Bioindustry Association